Clovis Oncology

Clovis Oncology, Inc. was an American biopharmaceutical company headquartered in Boulder, Colorado, dedicated to acquiring, developing and commercializing targeted anti-cancer agents. Founded in 2009 by Patrick J. Mahaffy, who also served as chief executive, the company went public on NASDAQ under the ticker CLVS and built a portfolio around precision oncology — medicines designed to exploit specific genetic vulnerabilities in tumors. Its lead product was Rubraca (rucaparib), an oral PARP inhibitor approved for certain ovarian and prostate cancers and later developed as a companion to BRCA-mutation testing. Clovis also advanced lucitanib, an investigational tyrosine kinase inhibitor studied in combination with other agents, and earlier held rights to agents such as CO-1686 (rociletinib) for EGFR-mutant lung cancer, a program whose regulatory path proved difficult. Commercially, Clovis competed in the PARP inhibitor field against AstraZeneca's Lynparza, GlaxoSmithKline's Zejula and Pfizer's Talzenna, and its revenue base remained modest relative to development spending. The company financed itself through equity offerings, royalty arrangements and debt, and its share price fell sharply over time as launch expectations disappointed. In late 2022 Clovis Oncology and certain subsidiaries filed for Chapter 11 bankruptcy protection in the United States, and its assets — including Rubraca — were sold. The brand therefore represents a specialist oncology developer that reached the market with a precision medicine but could not sustain itself commercially against larger competitors.

Clovis Oncology was established in 2009 by Patrick J. Mahaffy as a biopharmaceutical company built around in-licensing and developing targeted cancer drugs. It listed on NASDAQ under CLVS and assembled a pipeline of precision oncology candidates. One early program was CO-1686 (rociletinib), an EGFR inhibitor for non-small cell lung cancer with T790M mutations; the program faced regulatory setbacks and was ultimately not pursued as a commercial product. The company's most important asset became rucaparib, a PARP inhibitor developed as Rubraca. Rubraca received accelerated approval from the U.S. Food and Drug Administration for advanced ovarian cancer in patients with deleterious BRCA mutations, and later gained approvals in additional ovarian and prostate cancer settings, supported by companion diagnostic testing. Clovis also developed lucitanib, a tyrosine kinase inhibitor investigated in combination studies, though it did not become a marketed product. The company operated in a highly competitive PARP space alongside Lynparza, Zejula and Talzenna, and its commercial performance lagged the cost of its development and launch activities. It relied on equity and debt financing and royalty monetization to fund operations. By 2022, with cash reserves depleted and revenue insufficient, Clovis Oncology and certain affiliates filed for Chapter 11 bankruptcy in the United States. Its assets, including Rubraca, were sold through the bankruptcy process, ending the company as an independent commercial entity.

• 2022

  Company files for Chapter 11 bankruptcy and sells assets

• 2016

  Rubraca (rucaparib) receives accelerated FDA approval for BRCA-mutated advanced ovarian cancer

• 2009

  Clovis Oncology founded by Patrick J. Mahaffy

Specialist precision-oncology developer of targeted cancer therapies, competing in the PARP inhibitor class.

• Rubraca (rucaparib)

  Oral PARP inhibitor approved for certain ovarian and prostate cancers.

• Lucitanib

  Investigational tyrosine kinase inhibitor studied in combination regimens.

1. 1Clovis Oncology — Wikipediaen.wikipedia.org
2. 2Clovis launches $75M on-demand stock sale – BizWestbizwest.com
3. 3Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals - Pharmaceutical Business reviewpharmaceutical-business-review.com
4. 4FDA approves Rubraca for prostate cancer subsethealio.com